Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Net Margin: 2019-2025

Historic Net Margin for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to -2,973.05%.

  • Kymera Therapeutics' Net Margin fell 130272.00% to -2,973.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 124,000.84%, marking a year-over-year increase of 12419210.00%. This contributed to the annual value of -7,221.23% for FY2024, which is 703423.00% down from last year.
  • Kymera Therapeutics' Net Margin amounted to -2,973.05% in Q3 2025, which was down 345.33% from -667.60% recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Net Margin high stood at 193.43% for Q4 2024, and its period low was -2,973.05% during Q3 2025.
  • Its 3-year average for Net Margin is -715.07%, with a median of -432.37% in 2023.
  • In the last 5 years, Kymera Therapeutics' Net Margin skyrocketed by 51,299bps in 2021 and then crashed by 130,272bps in 2025.
  • Over the past 5 years, Kymera Therapeutics' Net Margin (Quarterly) stood at -222.88% in 2021, then soared by 685bps to -216.03% in 2022, then skyrocketed by 18,602bps to -30.01% in 2023, then soared by 22,343bps to 193.43% in 2024, then plummeted by 130,272bps to -2,973.05% in 2025.
  • Its Net Margin was -2,973.05% in Q3 2025, compared to -667.60% in Q2 2025 and -296.75% in Q1 2025.